Abstract:1685 Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma. Its cure rate has improved over the last two decades in the rituximab era. However, about one-third of patients are refractory/ relapsed ultimately. Early detection of such patients and applying more intensive treatment may help improve prognosis. 18F-FDG PET / CT is widely used in initial staging and post-treatment response assessment, while its value in prognosis is still challenge. The purpose of this study was to explore whether the baseline PET/CT parameters can identify refractory/ relapsed disease in advanced stage patients. Methods: Eighty-three advanced stage untreated DLBCL patients were enrolled in this study, including 43 males and 40 females, with a median age of 60 years. There were 18 cases of Ann Arbor stage III and 65 cases of stage IV. After baseline PET/CT examination, all patients received R-CHOP or R-CHOP-like regimen treatment in our hospital and were followed up for at least 3 years. Refractory/ relapsed disease was defined as progressive or stable disease during treatment, or relapse within 1 year of diagnosis after an initial CR. The tumor VOIs were semi automatically defined on the attenuation-corrected PET images by using a threshold of SUV ≥ 2.5 on local image features extraction (LifeX) software, with segmentation correction performed manually by consensus by two experienced nuclear medicine physicians. SUVmax, metabolic tumor volume (MTV) and tumor lesion glycolysis (TLG) were then calculated. The clinical data including Ann Arbor stage, B symptom, bulky mass, bone marrow involvement, important extranodal involvement, LDH level and NCCN-IPI score were also analyzed. Univariate and multivariate logistic regression analysis was used to identify the independent risk factors for refractory / relapsing patients. PFS and OS were estimated by the Kaplan-Meyer survival analyses, and the difference was compared using a log-rank test. Univariate and multivariate Cox regression models was used to identify the independent risk factors for PFS and OS. Results: There were 44 patients in non- refractory/ relapsed group and 39 patients in refractory/ relapsed group. The MTV and TLG of refractory/ relapsed group was significantly higher than that of non- refractory/ relapsed group (MTV: 1579.9 cm3 Vs. 484.7cm3, P =0.000; TLG: 7853.8 Vs. 3015.8, P =0.000). There was no significant difference of SUVmax between the two groups (15.9 Vs. 17.5, P= 0.248). In the univariate Logistic regression analysis, Ann Arbor stage = 4 \* ROMAN IV, B symptom, bone marrow involvement, important extranodal involvement, elevated LDH level, high NCCN-IPI score, high MTV and TLG were the independent risk factors in prediction refractory/ relapsing disease. In the multivariate Logistic regression analysis, only elevated LDH level and high TLG were the independent risk factors (elevated LDH: HR= 5.233, 95% CI= 1.234-22.183, P=0.025; TLG>2098: HR= 11.914, 95% CI=3.065-46.314, P=0.000). In the univariate Cox analysis, Ann Arbor stage = 4 \* ROMAN IV, B symptom, bone marrow involvement, important extranodal involvement, elevated LDH level, high NCCN-IPI score, high MTV and high TLG were the independent risk factors for PFS. In multivariate Cox analysis, only high TLG was the independent risk factors (HR= 3.049, 95%CI: 1.250-7.438, P=0.014). As to the OS, in the univariate Cox analysis, Ann Arbor stage = 4 \* ROMAN IV, B symptom, important extranodal involvement, elevated LDH level, high NCCN-IPI score, high MTV and high TLG were the independent risk factors. In multivariate analysis, only B symptom and elevated LDH were the independent risk factors (B symptom: HR= 3.494, 95%CI: 1.489-8.197, P=0.004; elevated LDH: HR= 9.805, 95% CI:1.320-72.831, P=0.026). Conclusions: High MTV and TLG in baseline PET/CT can predict the refractory/relapse disease in patients with advanced DLBCL, and can be used as important prognostic factors.

Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism

Persistent Lymphopenia after Chemotherapy And/or Radiotherapy Predicted Unfavorable Outcome in Breast Cancer Patients - a Retrospective Cohort Study

Prognostic Significance and Phenotypic Manifestations of MYC/BCL2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL) with Extranodal Organ Involvement: A Report of the International DLBCL Rituximab-CHOP Consortium Program Study

Risk Factors and Prognosis Value of Venous Thromboembolism in Patients with Advanced Non-Small Cell Lung Cancer: a Case-Control Study

Molecular Biomarker Exploration of Rituximab plus CHOP Therapy in Real-World Diffuse Large B-Cell Lymphoma Patients

Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism

Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma

Risk factors and mortality associated with venous thromboembolism in the elderly US population with chronic lymphocytic leukemia

Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma

Association Between White Blood Cell Counts at Diagnosis and Clinical Outcomes in Venous Thromboembolism - From the COMMAND VTE Registry-2

An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era

[Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].

A Clinical Study of Baseline PET/CT Parameters in the Prediction of Refractory/relapsed Diffuse Large B Cell Lymphoma of Advanced Stage Patients

Clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma

[Retrospective Analysis of Risk Factors for Venous Thromboembolism in 283 Patients with Lung Cancer During Systemic Therapy].

Prognosis And Risk Factors Of Radiation-Induced Lymphopenia In Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy

Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.

Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy

Clinical analysis of bleeding and thrombotic events in haematological-oncology patients with severe thrombocytopenia and a high risk of thrombosis

Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance

Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma